-
Sorafenib (BAY-43-9006): Applied Protocols for Cancer and An
2026-07-09
Sorafenib (BAY-43-9006) is a validated cancer biology research tool now showing promise as an antiviral agent. This guide delivers actionable workflows, troubleshooting strategies, and cross-domain insights for maximizing experimental rigor with APExBIO Sorafenib.
-
Transdermal PTEN mRNA Delivery via HA-LNPs for Melanoma Ther
2026-07-09
This study introduces a hyaluronated lipid nanoparticle (HA-LNP) system for transdermal delivery of PTEN mRNA, addressing immune evasion and resistance in melanoma. The approach leverages HA-mediated targeting to restore tumor suppressor function and enhance antitumor immunity, offering a promising platform for localized mRNA-based cancer immunotherapy.
-
Pharmacokinetic Variability of CSBTA Alkaloids in MASH Model
2026-07-08
This study provides a detailed pharmacokinetic analysis of Corydalis saxicola Bunting total alkaloids (CSBTA) in mouse models of metabolic dysfunction-associated steatohepatitis (MASH). The findings show that disease-induced changes in metabolism and transporter expression significantly alter systemic exposure and tissue distribution, with important implications for dosing in MASLD/MASH research.
-
Protein A/G Magnetic Beads: Practical Guidance for IP and Co
2026-07-08
Protein A/G Magnetic Beads (SKU K1305) offer an efficient solution for isolating IgG antibodies and their complexes from serum, cell culture supernatant, or ascites, with minimized non-specific binding. This product is ideal for immunoprecipitation (IP), co-immunoprecipitation (Co-IP), and chromatin immunoprecipitation (Ch-IP) workflows, but should not be used for diagnostic or medical applications.
-
GSTA1 Upregulation Drives Glutathione Loss in α-Amanitin Tox
2026-07-07
This study reveals that upregulated GSTA1 exacerbates α-amanitin-induced hepatotoxicity by depleting glutathione and promoting oxidative stress. The findings reposition GSTA1 from a classical detoxifier to a pathogenic factor, offering new mechanistic insight and potential therapeutic targets for acute liver injury.
-
Trichostatin A (TSA): Epigenetic Modulation Beyond Cancer Be
2026-07-07
Explore how Trichostatin A (TSA) is redefining epigenetic research, advancing beyond conventional cancer models to enable combination therapies and next-generation assay design. Gain new insights into TSA's mechanism and its translational significance for challenging tumor types.
-
ROS-Degradable Lipid Nanoparticles for Selective mRNA Delive
2026-07-06
The reference study introduces a combinatorial library of ROS-degradable lipid nanoparticles designed for the selective delivery of mRNA into tumor cells, exploiting elevated ROS levels to trigger intracellular release. This approach enables potent inhibition of mutant RAS signaling and demonstrates enhanced antitumor activity, offering a promising advance in targeted mRNA therapeutics.
-
SAR405: Vps34 Inhibitor Workflows for Autophagy Research
2026-07-06
SAR405 delivers nanomolar-precision Vps34 inhibition for dissecting autophagy and vesicle trafficking with unprecedented selectivity. This guide translates breakthrough findings and practical workflows into robust, reproducible results for cancer and neurodegeneration models.
-
BRD4-RAC1 Co-Inhibition Disrupts Oncogenic Epigenetic Axes i
2026-07-05
This study demonstrates that co-targeting the epigenetic regulator BRD4 and the small GTPase RAC1 suppresses growth, stemness, and tumorigenesis in multiple breast cancer subtypes. Mechanistically, combined inhibition disrupts the c-MYC/G9a/FTH1 axis and reduces HDAC1 expression, highlighting a robust approach for tackling epigenetic complexity in cancer.
-
SM-102 in mRNA Delivery: Advanced Workflows and Troubleshoot
2026-07-04
SM-102 enables high-efficiency mRNA delivery by optimizing lipid nanoparticle composition, as demonstrated in recent tumor suppressor replacement strategies. This guide translates the latest research into actionable protocols and troubleshooting tips for maximizing mRNA delivery performance in preclinical and therapeutic settings.
-
BFH772 (VEGFR2 inhibitor): Technical Use & Protocol Guidance
2026-07-03
BFH772 (VEGFR2 inhibitor) is a highly selective small molecule for precise inhibition of VEGFR2 kinase activity, supporting workflows in angiogenesis and tumor research that require targeted modulation of VEGFR2 signaling. It is not suitable for protocols needing water solubility or broad kinase inhibition, and care is required in storage and solvent selection.
-
Mifepristone (RU486): Beyond Contraception—Frontiers in Tumo
2026-07-03
Explore how Mifepristone (RU486) is redefining cancer and reproductive biology research through advanced cell cycle control and tumor growth inhibition. This article delivers a unique, data-driven perspective on Mifepristone's mechanistic depth, bridging molecular insights with next-generation assay design.
-
Strategic Insight: Mitochondrial Membrane Potential in Trans
2026-07-02
This article bridges mechanistic discoveries on sodium-induced mitochondrial dysfunction with actionable guidance for translational researchers. Leveraging new findings on Na+ overload’s impact on cell fate, we highlight how precise mitochondrial membrane potential detection—enabled by the TMRE mitochondrial Membrane Potential Assay Kit—can transform experimental workflows, disease modeling, and therapeutic development.
-
P2RX1 Drives Mitochondrial Apoptosis in Ph+ ALL via Ca2+/CaM
2026-07-02
Li et al. (2025) identify P2RX1 as a critical modulator of mitochondrial apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), acting through Ca2+/CaMKII-mediated suppression of PI3K/Akt signaling. This mechanistic insight highlights P2RX1 as a promising therapeutic target for overcoming tyrosine kinase inhibitor resistance in Ph+ ALL.
-
Cy3 NHS ester (non-sulfonated): Practical Guide for Protein
2026-07-01
Cy3 NHS ester (non-sulfonated) enables efficient, high-sensitivity fluorescent labeling of proteins, peptides, and oligonucleotides via amine-reactive chemistry, especially for applications requiring robust orange emission. It is best suited for workflows compatible with organic co-solvents such as DMSO or DMF, and should not be used when aqueous-only conditions are essential or for extremely labile protein targets.